molecules of the month


kinetoplastid-selective proteasome inhibitor

oral antileishmanial in Ph. I in HV

From 3M cmpd antiprolif. screen + opt.

J. Med. Chem., Jul. 29, 2020

Novartis (GNF), San Diego, CA

Structure of LXE408
1 min read

LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with a specialized formulation but would have increased the cost and limited use in developing countries. A single methyl group dramatically improved the dissolution properties without compromising activity, leading to LXE408. Interestingly, a 3.4A cryo-EM structure was obtained of LXE408 with the kinetoplastid proteosome showing its non-competitive mode of binding in contrast to mammalian proteosome inhibitors like bortezomib.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: